|
Accession number;04A0309581
|
| Title;Effects of Ozamarin and Xanbon Injectable on Experimental Cerebral Ischemia Model in Rats |
| Author;
TANAKA YOSHIYUKI
(Sawai Pharm. Co., Ltd.)
OGURA TAKEHARU
(Sawai Pharm. Co., Ltd.)
OTSUBO YOSHIKAZU
(Sawai Pharm. Co., Ltd.)
MATSUOKA YUTAKA
(Sci. Univ. of Tokyo, Fac. of Pharm. Sci.)
KONO SHIGEKATSU
(Kyoto Pharmaceutical Univ., JPN)
|
Journal Title;Japanese Pharmacology & Therapeutics
|
Journal Code:Z0947A
|
ISSN:0386-3603
|
|
VOL.32;NO.2;PAGE.81-85(2004)
|
| Figure&Table&Reference;FIG.3, REF.9 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Effects of Ozamarin and Xanbon injectable, the preparations of a selective thromboxane (TX)A2 synthetase inhibitor, on experimental models of cerebral ischemia were studied. Cerebral ischemia was induced by the 1 or 5 hour occlusion and reperfusion of the bilateral carotid artery. The respective drugs at 1, 3 or 10 mg/kg were administered. Both drugs dose-dependently inhibited the increase in plasma TXB2 (stable metabolite of TXA2) level after the 5 hour ischemia in rats. The plasma level of 6-keto prostaglandin (PG) F1.ALPHA. (stable metabolite of PGI2) was increased by the administration of the drugs. After the bilateral carotid artery occlusion (BCAO)for 1 hour, the local blood flow of the middle cerebral artery was reduced. Both drugs dose-dependently inhibited the decrease of the blood flow after 15 min reperfusion. The administration of each drug at the dose of 10 mg/kg restored the decreased blood flow to the basal level. Both drugs have protective effects on cerebral ischemia in rats. No differences between Ozamarin and Xanbon injectable were observed in the BCAO rat model. (author abst.) |
|
|
|
Related Articles;
|
